Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJardine Math.sr Regulatory News (JAR)

Share Price Information for Jardine Math.sr (JAR)

Share Price is delayed by 15 minutes
Get Live Data
62.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: $18.42b
JAR Live PriceLast checked at - London Stock Exchange

Intraday Jardine Math.sr Share Chart

Directorate Change

5 Mar 2020 09:21

RNS Number : 1288F
Jardine Matheson Hldgs Ltd
05 March 2020
 

Jardine Matheson Holdings Limited

Directorate Change

 

Jardine Matheson Holdings Limited (the 'Company') announces that, with effect from 15th June 2020, the roles of Executive Chairman and Managing Director, which have been held on a combined basis by Ben Keswick since December 2018, will revert to being separate roles.

 

Ben Keswick will remain as Executive Chairman and John Witt, currently Group Finance Director, will take on the role of Managing Director.

 

John joined Jardines in 1993 and held a range of senior roles across the Group's core businesses and geographies, including as chief financial officer of Hongkong Land and Mandarin Oriental, before being appointed to the Jardine Matheson Board in 2016.

 

John will also be a director of Jardine Strategic Holdings Limited and the Group's listed subsidiaries, Hongkong Land Holdings Limited, Dairy Farm International Holdings Limited and Mandarin Oriental International Limited. He will also continue to be a commissioner of Astra and chairman of the Astra Excom.

 

Graham Baker will replace John as Group Finance Director and will join the Group on 1st June 2020 from Smith + Nephew in the United Kingdom, where he has been a board member and chief financial officer since March 2017. Graham will join the Board of the Company.

 

Prior to joining Smith + Nephew, Graham worked for 20 years for AstraZeneca PLC in a range of senior roles in the UK and internationally, including in Japan and Singapore, and then as chief financial officer of generic pharmaceuticals company Alvogen.

 

Commenting on the changes, Ben Keswick said:

"I am confident that these appointments will strengthen and enhance the effectiveness of the Group's leadership as we respond to the challenges and opportunities we face in positioning Jardines for continuing long term success."

 

- end -

 

For further information please contact

 

Investor enquries:

Jonathan Lloyd

Jardine Matheson Limited

 

(852) 2843 8223

 

Media enquiries:

Brunswick

Tom Burns

 

(44) 207 404 5959

David Ashton

(852) 3512 5063

 

This and other Group announcements can be accessed at www.jardines.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAUPUBAWUPUURA
Date   Source Headline
29th May 202610:53 amRNSTotal Voting Rights
29th May 202610:47 amRNSDirector/PDMR Shareholding
28th May 202611:31 amRNSTransaction in Own Shares
27th May 202610:27 amRNSDirector/PDMR Shareholding
26th May 20267:00 amRNSAcquisition of I-MED Radiology Network
22nd May 202610:23 amRNSInterim Management Statement
19th May 202612:22 pmRNSINTERIM MANAGEMENT STATEMENT
18th May 202612:57 pmRNSNotification of Issuance of Equity Securities
18th May 202612:30 pmRNSDirector/PDMR Shareholding
7th May 20261:01 pmRNSAdditional Listing
7th May 202612:49 pmRNSDirector/PDMR Shareholding
7th May 202612:44 pmRNSResult of AGM
5th May 202610:54 amRNSTransaction in Own Shares
5th May 202610:19 amRNSTransaction in Own Shares
30th Apr 202611:51 amRNSTotal Voting Rights
30th Apr 202611:50 amRNSTransaction in Own Shares
30th Apr 202610:47 amRNSJC&C Interim Management Statement
29th Apr 202612:28 pmRNSPT Astra 2026 First Quarter Financial Statements
29th Apr 202611:59 amRNSTransaction in Own Shares
29th Apr 202610:48 amRNSDividend
28th Apr 202611:35 amRNSTransaction in Own Shares
28th Apr 20267:00 amRNSTransaction in Own Shares
24th Apr 202611:26 amRNSDividend
22nd Apr 202611:12 amRNSTransaction in Own Shares
21st Apr 202610:57 amRNSTransaction in Own Shares
20th Apr 202611:01 amRNSTransaction in Own Shares
14th Apr 202611:31 amRNSTransaction in Own Shares
13th Apr 202611:27 amRNSTransaction in Own Shares
10th Apr 202611:23 amRNSTransaction in Own Shares
8th Apr 202611:53 amRNSTransaction in Own Shares
8th Apr 202610:25 amRNSAnnual Financial Report
8th Apr 20267:00 amRNSTransaction in Own Shares
7th Apr 20268:02 amRNSTransaction in Own Shares
1st Apr 202611:17 amRNSTransaction in Own Shares
1st Apr 202610:34 amRNSCirc re. Scrip Dividend Scheme
1st Apr 202610:21 amRNSDirector/PDMR Shareholding
31st Mar 202611:59 amRNSDirector/PDMR Shareholding
31st Mar 202611:53 amRNSTotal Voting Rights
31st Mar 202611:46 amRNSTransaction in Own Shares
30th Mar 202611:08 amRNSTransaction in Own Shares
27th Mar 20269:43 amRNSDirector/PDMR Shareholding
25th Mar 202611:05 amRNSDirector/PDMR Shareholding
25th Mar 202610:31 amRNSTransaction in Own Shares
25th Mar 20267:00 amRNSTransaction in Own Shares
20th Mar 202611:07 amRNSTransaction in Own Shares
20th Mar 20269:26 amRNSDirector/PDMR Shareholding
17th Mar 20269:55 amRNSDirector/PDMR Shareholding
16th Mar 20269:57 amRNSDirector/PDMR Shareholding
16th Mar 20269:57 amRNSDirector/PDMR Shareholding
13th Mar 20269:42 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.